<DOC>
	<DOCNO>NCT00130728</DOCNO>
	<brief_summary>This Phase III , multicenter , placebo-controlled , double-blind , randomize study . Approximately 650 patient randomize 1:1 ratio one two treatment arm .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Bevacizumab Combination With Tarceva Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed write informed consent Cytologically histologically confirm NSCLC Clinical radiographic progression firstline chemotherapy chemoradiotherapy NSCLC Consent provide archival tissue analysis require participation study Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Age ≥ 18 year Use acceptable mean contraception men woman childbearing potential International normalize ratio ( INR ) great 1.3 aPTT great upper limit normal within 28 day prior enrollment patient low‑molecular‑weight heparin fondaparinux Squamous cell carcinoma Prior treatment investigational market inhibitor Epidermal Growth Factor Receptor ( EGFR ) pathway antiangiogenesis agent Systemic chemotherapy , radiotherapy , investigational treatment within 28 day prior randomization Local palliative radiotherapy within 14 day prior randomization persistent adverse effect radiotherapy resolve Grade 2 less follow completion treatment Whole brain radiotherapy stereotactic radiosurgery brain metastasis within 4 week Day 0 Neurosurgery brain metastasis within 24 week Day 0 Brain biopsy within 12 week Day 0 Current use dexamethasone treatment associate brain metastasis History gross hemoptysis within 3 month prior randomization unless definitively treat surgery radiation History follow within 6 month prior Day 0 : serious systemic disease , uncontrolled hypertension , unstable angina , New York Heart Association ( NYHA ) Grade 2 great Congestive Heart Failure ( CHF ) , unstable symptomatic arrhythmia require medication , clinically significant peripheral vascular disease , abdominal fistula , gastrointestinal perforation , intraabdominal abscess Evidence bleed diathesis coagulopathy serious acute internal bleeding within 6 month prior randomization Central Nervous System ( CNS ) bleeding ; history clinical evidence CNS stroke ( hemorrhagic thrombotic ) within last 6 month Progressive neurologic symptom patient history brain metastasis Fulldose anticoagulation warfarin Chronic daily use aspirin fulldose nonsteroidal antiinflammatory drug ( NSAIDs ) antiplatelet activity Inpatient surgical procedure , open biopsy , significant traumatic injury within 28 day prior randomization Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior randomization Anticipation need major surgical procedure course study Serious , nonhealing wound , ulcer , bone fracture Inability take oral medication requirement intravenous ( IV ) alimentation total parenteral nutrition lipid , prior surgical procedure affect absorption Pregnancy breastfeed Presence another invasive cancer within 5 year prior randomization Evidence confusion disorientation , history major psychiatric illness may impair patient 's understanding Informed Consent Form ability comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Avastin</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>